Outlook Therapeutics
OTLK
76 hedge funds and large institutions have $29.3M invested in Outlook Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 5 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 18
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
16% more capital invested
Capital invested by funds: $25.3M → $29.3M (+$4.01M)
1% more funds holding
Funds holding: 75 → 76 (+1)
0.02% less ownership
Funds ownership: 0.55% → 0.53% (-0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$188K |
| 2 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$101K |
| 3 |
State Street
Boston,
Massachusetts
|
+$69.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$41.7K |
| 5 |
Squarepoint
New York
|
+$37.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Vista Finance
Clayton,
Missouri
|
-$724K |
| 2 |
Renaissance Technologies
New York
|
-$187K |
| 3 |
Millennium Management
New York
|
-$183K |
| 4 |
Two Sigma Advisers
New York
|
-$179K |
| 5 |
BlackRock
New York
|
-$115K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
AQR Capital Management
Greenwich,
Connecticut
| – | -$53K | -2,602 | Closed |
|
|
VF
77
Virtu Financial
New York
| – | -$22K | -1,056 | Closed |
|
|
HF
78
HRT Financial
New York
| – | -$20K | -1,006 | Closed |
|
|
EWM
79
Endurance Wealth Management
Providence,
Rhode Island
| – | -$15K | -750 | Closed |
|
80
UBS Group
Zurich,
Switzerland
| – | -$1K | -72 | Closed |
|
OTLK Hedge Fund Activity: Q3 2022 in Review
76 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2022, worth a combined $29.3M — up 16% from $25.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new OTLK positions and 5 closed out — a net gain of 2 holders — while 26 added to existing stakes and 18 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $188K. The largest seller was Vista Finance, cutting an estimated $724K.
- 76 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2022, up from 75 in Q2 2022.
- Funds reported $29.3M of Outlook Therapeutics stock for Q3 2022, up 16% quarter-over-quarter.
- 7 funds opened new Outlook Therapeutics positions in Q3 2022 and 5 closed out, a net change of +2 holders.
- The largest Outlook Therapeutics buyer in Q3 2022 was Fidelity Investments, an estimated $188K added.
- The largest Outlook Therapeutics seller in Q3 2022 was Vista Finance, an estimated $724K sold.
Based on aggregated 13F filings for Q3 2022.